CoChat

CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization

Liekens, S., Schols, D., Hatse, S. · 2010 · Current Pharmaceutical Design
Cited by 213

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Chemokines are key players in the attraction and activation of leukocytes and are thus implicated in the recruitment of immune cells at sites of infection and/or inflammation. They exert their action by binding to seven-transmembrane G protein-coupled receptors. The chemokine stromal cell-derived factor-1 (SDF-1)/CXCL12 represents the single natural ligand for the chemokine receptor CXCR4. CXCL12 possesses angiogenic properties and is involved in the outgrowth and metastasis of CXCR4-expressing tumors and in certain inflammatory autoimmune disorders, such as rheumatoid arthritis. CXCR4 expression on tumor cells is upregulated by hypoxia and angiogenic factors, such as vascular endothelial growth factor (VEGF). CXCR4 also acts as a co-receptor for entry of human immunodeficiency virus (HIV) in CD4+ T cells. Finally, CXCL12/CXCR4 interactions were shown to play an important role in the migration of hematopoietic stem cells and their progenitors from, and their retention within, the bone marrow, a site characterized by high CXCL12 expression. As such, CXCR4 inhibitors may be utilized to inhibit HIV-1 infection, tumor growth and metastasis and to mobilize hematopoietic stem cells from the bone marrow in the circulation, where they can be collected for autologous stem cell transplantation. Here, we discuss the different aspects of CXCL12/CXCR4 biology as well as the development and anti-cancer/stem cell mobilizing activity of CXCR4 antagonists. Keywords: Angiogenesis, CXCL12, CXCR4, metastasis, progenitor cells, SDF-1, small molecule inhibitors, ELR, multiple myeloma, HUVEC, FGF-2, KR158, GL261, rheumatoid synovium, AMD3100, SCLC, Asp262, Glu288, non-Hodgkin's lymphoma, cholangiocarcinoma, acute lymphoblastic, acute myelogenous leukemia, bortezomib, melphalan, doxorubicin, dexamethasone, sorafenib, TN14003, MDA-MB-231, AMD070, WZ811, KRH-1636, KRH-3955, PRO2000, ALX40-4C, CTCE-9908, Plerixafor, BKT140, POL6326, TG-0054

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/138161210794455003

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 213

Metadata

Authors
Liekens, S., Schols, D., & Hatse, S.
Venue
Current Pharmaceutical Design
Published
2010-12-01
Volume
16
Issue
35
Pages
3903-3920
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2118826168
Cited by
213
References
8
FWCI
5.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization. https://app.cochat.ai/papers/10.2174/138161210794455003
The paper
Liekens, S., Schols, D., & Hatse, S. (2010). CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization. Current Pharmaceutical Design. https://doi.org/10.2174/138161210794455003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.